Table 1.

Study description

StudyaIndicationTreatmentsTumor assessment frequencyResponse rates (%) control, experimentalPFS HR
AVF2107g (21) n = 813/750First line CRCIFL +/− bevacizumabEvery 6 weeks for 24 weeks, then every 12 weeks34.8, 44.8; P = 0.0040.54; P < 0.0001
AVF2119g (22) n = 462/412Second line BCCapecitabine +/− bevacizumabEvery 6 weeks for 24 weeks, then every 9 weeks9.1, 19.8; P = 0.0010.98; P = 0.86
AVF2192g (23) n = 209/189First line CRC5-FU/LV +/− bevacizumabEvery 8 weeks15.2, 26.0; P = 0.0550.50; P = 0.0002
SO14999 (24) n = 511/477BC, 33% first line, otherwise later linesDocetaxel +/− capecitabineEvery 6 weeks for 48 weeks, then every 12 weeks30, 42; P = 0.0060.65b; P = 0.0001
BR21 (25) n = 731/525Second line NSCLCErlotinib vs. placeboEvery 8 weeks<1, 8.9; P < 0.0010.61; P < 0.001
H0648g (26) n = 469/361First line HER2+ BCAC +/− trastuzumab pac +/− trastuzumabAn 8-week assessment, then every 12 weeks32, 50; P < 0.0010.51b; P < 0.001

Abbreviations: CRC, colorectal cancer; BC, breast cancer; IFL, irinotecan, 5-FU, leucovorin; LV, leucovorin; AC, anthracycline, cyclophosphamide; pac, paclitaxel.

  • an = the number of patients randomized in the study over the number of patients remaining for the analysis after data processing. For study AVF2107g, n = 813 excludes 110 patients randomized to a 5-FU/LV + bevacizumab arm that was dropped from the study. Other patient exclusion reasons are described in the text.

  • bHR for analysis of time to progression.